Financials
Financial year 2025
COMPASS Pharma from Sint-Katelijne-Waver, company number BE0686912527, closed financial year 2025 with a result of € 39,042 after tax. For that financial year COMPASS Pharma recorded a gross margin of € 49,378 and equity of € 236,480. Compared with financial year 2024, the result moved from € 23,001 to € 39,042. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 4, 2026.
€ 236,480
▼ 11% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 39,042
▲ 70% vs 2024
Profit after tax over the fiscal year.
€ 86,600
▼ 16% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 69,042 paid out
More than the year’s profit went to the shareholders; reserves fell.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 146,818
▲ 250% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 2,561
▼ 77% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 85,067 | € 42,603 | € 32,006 | € 49,378 | ▲ 54% |
| Profit after taxes | € 56,186 | € 27,380 | € 23,001 | € 39,042 | ▲ 70% |
| Equity | € 327,593 | € 354,973 | € 266,480 | € 236,480 | ▼ 11% |
| Total debts | € 6,392 | € 8,105 | € 84,492 | € 188,421 | ▲ 123% |
| Cash | € 197,740 | € 293,526 | € 103,575 | € 86,600 | ▼ 16% |
| Retained profit | € 308,993 | € 336,373 | € 247,880 | € 217,880 | ▼ 12% |
| Dividend | € 0 | € 0 | € 111,494 | € 69,042 | ▼ 38% |
| Bank debt | € 34 | € 618 | € 48 | € 0 | ▼ 100% |
| Balance sheet total | € 333,985 | € 363,078 | € 350,972 | € 424,901 | ▲ 21% |
Key figures of COMPASS Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to COMPASS Pharma?
What happened at COMPASS Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 39,042 (▲ 70% vs 2024). Source: NBB ↗
- New establishment in Londerzeel. KBO
- New establishment in Sint-Katelijne-Waver. KBO
- Melissa Penninck became a director. NBB
- Sandy Sercy became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 56,186 profit in 2022 to € 39,042 profit in 2025.
Paid € 59,901 in corporate taxes since 2022.
Best year ever: 2022, with € 56,186 profit.
Paid out € 180,536 in dividends to the owners in total.
A new publication or filing at COMPASS Pharma? We notify you, reason included.
Follow COMPASS PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind COMPASS Pharma are Melissa Penninck and Sandy Sercy. Melissa Penninck is also behind Farmelis.
Directors
According to the 2025 annual accounts
since 2018
Sandy Sercy
Director
since 2018
Establishments
Establishment units
Physical locations of this company
Kanadastraat 24
2860 Sint-Katelijne-Waver
Haan 69
1840 Londerzeel
Active since 1 January 2018
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0686.912.527
- VAT number
- BE 0686.912.527
- Registered office
- Kanadastraat 24, 2860 Sint-Katelijne-Waver
- Names & denominations
- COMPASS Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 December 2017
- Peppol
- Active · Active since 3 Dec 2024
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten van hoofdkantoren